Eficacia clínica de la ezetimiba y objetivos terapéuticos de colesterol unido a LDL

The addition of ezetimibe in patients treated with statins produces an additional 25% reduction in total cholesterol, a 36% reduction in low-density lipoprotein cholesterol (LDL-C), and a 24% reduction in triglycerides. This decrease enables 40% of the patients who do not achieve their LDL-C goals according to their coronary risk to achieve them after ezetimibe therapy. Combined treatment with ezetimibe and statins improves the control of hyperlipidemias.